type 2 diabetes – Medxy AI

Diabetes & Endocrinology news OB/GYN & Women’s Health

Linking Endometriosis Subtypes to Increased Risk of Type 2 Diabetes: Insights from the ARCHES Study

By MedXY 08/08/2026

The ARCHES retrospective cohort study reveals that endometriosis significantly elevates the risk of type 2 diabetes, particularly in specific subtypes and among premenopausal women with lower BMI, highlighting the importance of subtype-specific metabolic risk assessment.

Diabetes & Endocrinology news

Optimizing Type 2 Diabetes Treatment: Comparing Precision Approaches in the TriMaster Trial

By MedXY 08/07/2026

This article evaluates precision treatment strategies for type 2 diabetes glucose-lowering therapy, demonstrating that clinical feature-based models outperform cluster and genetic-based methods in predicting HbA1c response, guiding more effective personalized therapy choices.

Diabetes & Endocrinology news OB/GYN & Women’s Health

Leveraging Polygenic Scores to Predict Diabetes Risk After Gestational Diabetes: Insights from a 30-Year Cohort Study

By MedXY 08/05/2026

Polygenic scores can predict type 1 diabetes risk after gestational diabetes, especially when combined with clinical factors, but show limited utility for type 2 diabetes prediction.

Diabetes & Endocrinology news Ophthalmology

Evaluating the Risk of Anterior Ischemic Optic Neuropathy with GLP-1 Receptor Agonists in Type 2 Diabetes: Insights from a Swedish Nationwide Cohort Study

By MedXY 08/05/2026

A large Swedish cohort study assesses whether glucagon-like peptide-1 receptor agonists increase the risk of anterior ischemic optic neuropathy in type 2 diabetes. Although a borderline elevated relative risk was observed, absolute incidence remained low and confounding factors likely influenced results.

Diabetes & Endocrinology Internal Medicine news

Metabolic Implications of Hepatic, Pancreatic, and Abdominal Fat Depots in Asian Indians Across Normoglycaemia, Prediabetes, and Type 2 Diabetes

By MedXY 08/03/2026

This study reveals that Asian Indians with prediabetes or type 2 diabetes show significantly higher liver and abdominal fat despite similar BMI, highlighting liver fat's key role in dysglycaemia and the importance of early intervention.

Diabetes & Endocrinology Internal Medicine news

Evaluating GLP-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabetes: Insights from a Veterans Health Administration Target Trial Emulation

By MedXY 08/03/2026

A large study in veterans with type 2 diabetes found that adding GLP-1 receptor agonists to basal insulin did not improve insulin discontinuation rates compared to SGLT-2 inhibitors or DPP-4 inhibitors over three years.

Cardiology Diabetes & Endocrinology news

Dapagliflozin and Lipoprotein Metabolism in Type 2 Diabetes: Preserving LDL Catabolism and Normalizing VLDL Processing

By MedXY 07/31/2026

This study demonstrates that dapagliflozin does not impair LDL catabolism but favorably shifts VLDL1 and VLDL2 catabolism toward normal physiology in type 2 diabetes, potentially contributing to reduced atherosclerosis risk.

Diabetes & Endocrinology news

Mild Cold Exposure with Shivering Lowers 24-Hour Glucose Levels in Type 2 Diabetes: A Novel Adjunctive Therapy

By MedXY 07/22/2026

Acute mild cold exposure with shivering significantly reduces 24-hour glucose levels and improves glycemic profiles in individuals with type 2 diabetes, but not in prediabetic subjects, suggesting a potential non-pharmacological intervention for glucose control.

Cardiology Diabetes & Endocrinology news

Oral Semaglutide and Cardiovascular Benefits in the SOUL Trial: Impact of Baseline and Changes in HbA1c and BMI on Clinical Outcomes

By MedXY 07/22/2026

This analysis of the SOUL trial shows oral semaglutide reduces major cardiovascular events, with greater benefits linked to higher baseline HbA1c and larger HbA1c reductions, while BMI changes did not significantly affect outcomes.

Cardiology Clinical Updates Diabetes & Endocrinology news

Impact of Medically Tailored Groceries on Glycemic Control in Medicaid-Insured Adults with Type 2 Diabetes: Insights from a Randomized Controlled Trial

By MedXY 07/21/2026

Medically tailored groceries modestly improve HbA1c and significantly enhance food and nutrition security among Medicaid-insured adults with type 2 diabetes, supporting 'Food Is Medicine' strategies in chronic disease management.

Diabetes & Endocrinology Nephrology news

IgG N-Glycosylation Profiles as Predictive Biomarkers for Diabetic Nephropathy in Type 2 Diabetes: Insights from a Pooled Prospective Cohort Analysis

By MedXY 07/19/2026

A pooled analysis of four cohorts reveals that specific IgG N-glycosylation patterns are significantly associated with incident diabetic nephropathy, highlighting immune-related mechanisms in disease progression.

Diabetes & Endocrinology news Ophthalmology

GLP-1 Receptor Agonists and the Risk of Ischemic Optic Neuropathy in Type 2 Diabetes: Evidence from a Target Trial Emulation

By MedXY 07/17/2026

This study evaluates the association between GLP-1 receptor agonists and ischemic optic neuropathy risk compared to SGLT2 and DPP-4 inhibitors, revealing a small but statistically significant increased risk with GLP-1RAs, particularly among older men with cardiovascular or eye conditions.

Diabetes & Endocrinology Gastroenterology news

EndoBarrier Duodenal-Jejunal Bypass Liner: A Novel Endoscopic Adjunct for Improved Glycemic Control and Weight Loss in Type 2 Diabetes with Obesity

By MedXY 07/15/2026

The ENDO trial demonstrates that the EndoBarrier duodenal-jejunal bypass liner significantly improves glycemic control and induces meaningful weight loss in patients with poorly controlled type 2 diabetes and obesity, with an acceptable safety profile.

Diabetes & Endocrinology news

Unveiling the Role of GIP in Regulating Postprandial Splanchnic Blood Flow in Type 2 Diabetes

By MedXY 07/08/2026

This study reveals that endogenous glucose-dependent insulinotropic polypeptide (GIP) significantly enhances postprandial splanchnic blood flow in people with type 2 diabetes, influencing insulin secretion without affecting glucose levels.

Clinical Updates news

Glucagon-like Peptide-1 Receptor Agonists Versus Dipeptidyl Peptidase-4 Inhibitors Following Liver Resection for Hepatocellular Carcinoma in Type 2 Diabetes: Insights from a Target Trial Emulation Study

By MedXY 07/05/2026

Postoperative GLP-1RA initiation after liver resection for hepatocellular carcinoma in type 2 diabetes patients is associated with improved recurrence-free and overall survival compared to DPP-4 inhibitors, indicating potential incremental benefits of GLP-1RAs in this setting.

Diabetes & Endocrinology Gastroenterology news

Global Insights into MASLD: Predictors of Fibrosis, Clinical Events, and Mortality from the Global-MASLD Study

By MedXY 07/03/2026

The Global-MASLD study identifies key predictors of advanced fibrosis and mortality in metabolic dysfunction-associated steatotic liver disease, highlighting the prognostic value of noninvasive fibrosis markers across diverse populations.

Cardiology Diabetes & Endocrinology news

Continuous Glucose Monitoring-Derived Time in Range Predicts Longitudinal Changes in Arterial Stiffness in Type 2 Diabetes

By MedXY 07/01/2026

This study demonstrates that continuous glucose monitoring-derived time in range (TIR) is independently associated with progression of arterial stiffness in type 2 diabetes, highlighting TIR as a valuable metric beyond HbA1c for cardiovascular risk management.

Diabetes & Endocrinology news

Metabolic State-Dependent Mechanisms of Liraglutide in Enhancing Insulin Secretion and Glycemic Control

By MedXY 06/27/2026

Liraglutide’s efficacy in type 2 diabetes varies with metabolic state, engaging brain-mediated insulin secretion in healthy individuals, direct islet action in glucose intolerance, and insulin-independent pathways in advanced disease stages, guiding tailored therapeutic strategies.

Diabetes & Endocrinology news

Gender Differences in Hypoglycaemia Among Type 1 and Insulin-Treated Type 2 Diabetes: Insights from the Hypo-METRICS Study

By MedXY 06/24/2026

This study evaluates gender-based differences in hypoglycaemia symptoms and frequency among people with type 1 and insulin-treated type 2 diabetes using continuous glucose monitoring in real-world settings.

Diabetes & Endocrinology news

Comparative 1-Year Outcomes of Semaglutide, Tirzepatide, and Sleeve Gastrectomy in Obese Adults with Type 2 Diabetes: Insights from Real-World Data

By MedXY 06/20/2026

A retrospective cohort study evaluating 1-year weight loss, glycaemic control, and safety outcomes among adults with obesity and type 2 diabetes treated with semaglutide, tirzepatide, or sleeve gastrectomy, highlighting higher efficacy with surgery but varying safety profiles.